Discontinue if skin rash, mucosal lesions or any signs of hypersensitivity occur. Monitor renal function in patients who will undergo major surgery, cardiac failure, receiving diuretics or drugs able to cause kidney damage, in mild (serum creatinine 150-300 μmol/L) & moderate (serum creatinine 300-700 μmol/L) renal impairment. Discontinue if renal function deteriorates during treatment. Perform clinical monitoring & laboratory assessment in patients w/ blood coagulation disorders, hepatic impairment (eg, liver cirrhosis). Regularly assess Hb, creatinine & liver enzymes during long-term treatment (>3 mth). Increased risk of GI bleeding, ulceration & perforation in patients w/ history of ulcer or concomitant treatment w/ oral corticosteroids, anticoagulants (eg, warfarin), SSRIs, antiplatelet agents (eg, acetylsalicylic acid). Patients w/ history of GI toxicity; GI disease (ulcerative colitis, Crohn's disease); HTN &/or heart failure; bronchial asthma; SLE & mixed connective tissue disorders; increased bleeding disorders. Uncontrolled HTN, CHF, established ischaemic heart disease, peripheral arterial disease &/or cerebrovascular disease. Elderly >65 yr.